Kornimate/medical-research-clean huggingface dataset:
medication adherence given individual systemchange(tm) in advancing nephropathy (magician) pilot study

Conditions: Chronic Kidney Disease(CKD)

Summary: the purpose of this 2-group, randomized, controlled trial is to evaluate the refined systemchange™ against attention control patient education in ckd patients taking raas medications.

in this study, the investigators will test a refined systemchange™ in patients taking raas inhibiting medications. participants will be recruited from two sources: 1) the largest and most comprehensive health care system in the state and 2) one of the largest essential health care systems in the country. data are collected at baseline, 8 weeks (immediately post-intervention), and 12 weeks.

Eligibility criteria:
inclusion criteria: * age \> 18 years * prescribed at least 1 daily raas inhibiting medication * ckd diagnosis estimated glomerular filtration rate (egfr) category g1 to g4 * raas inhibiting medication adherence of \<.85 documented during the screening phase * proteinuria defined as a urine protein-to-creatinine ratio \> 150 mg/g or urine albumin-to-creatinine ratio \>30mg/g * able to speak, hear, and understand english determined by the ability to participate and comprehend conversation about potential inclusion in the study * self-reported ability to open a pill cap * able to self-administer raas inhibiting medications * willing to use a study phone * has no cognitive impairment as determined by a score of 4 or greater on the 6-item telephone mental status screen derived from the mini-mental status exam (cognitive screener) * has no other diagnoses that may shorten life span, such as metastatic cancer * is not currently hospitalized * receives care through two approved health care systems exclusion criteria: * participants with kidney failure defined by gfr \<15 ml/min/1.73 * participants will be excluded if they are receiving dialysis or have dialysis access placed (e.g. graft or arteriovenous fistula) in anticipation of starting dialysis. * kidney and kidney-pancreas transplant recipients will be excluded.
evaluation of the zynex blood volume monitor in healthy adult volunteers during a blood draw

Conditions: Blood Loss

Summary: to determine if a manual blood loss can be detected using the non-invasive blood monitor.


Eligibility criteria:
inclusion criteria: * healthy volunteer * between 18 to 50 years of age * weight between 157 to 220 lbs exclusion criteria: * unstable or untreated cardia disease * alcohol consumption in 24 hours prior to screening * tobacco use in 4 hours prior to screening * pregnancy * infection * hemoglobin \< 12.5 g/dl at time of procedure

Keywords: blood loss, hemorrhage, hemorrhagic shcok
meaning of recovery after lung cancer surgery

Conditions: Recovery; Lung Cancer; Surgery

Summary: the purpose of this study is to find out the meaning of recovery after lung cancer surgery from a patient's point of view. the results of this study would help improve postoperative recovery in lung cancer patients.

in patients undergoing video-assisted thoracic surgery (vats) lung resection for lung cancer, the survey on the 'meaning of recovery after surgery' are conducted before surgery, 2 days after surgery, and 30 days after surgery. the questionnaire includes importance score of each question regarding the meaning of recovery after lung cancer surgery. after 2 days of surgery and 30 days after surgery, the questionnaire about the recovery score and the part where the patients felt difficulties are conducted to investigate what recovery means from a patient's point of view. length of hospital and icu stay and postoperative complications are also evaluated.

Eligibility criteria:
inclusion criteria: * patients aged 19 to 80 years undergoing video-assisted thoracic surgery (vats) lung resection for lung cancer * patients who can provide written consent to participate in clinical trials, understand the procedures of this clinical trial, and properly fill out patient-reported questionnaires or respond appropriately to interviews exclusion criteria: * patients who did not consent to the trial * patients who have difficulty filling out questionnaires or answering interviews about the meaning of recovery * patients judged to be inappropriate for this clinical trial based on the opinion of the investigator or investigator
primary care amoxicillin challenge

Conditions: Amoxicillin Allergy

Summary: the purpose of this project is to identify clinic patients reporting penicillin allergy who are low risk for allergic reaction, and then invite them to participate in an oral amoxicillin challenge in their primary office without need for referral to allergy/immunology. if the patient is able to tolerate oral amoxicillin, the antibiotic allergy in question will be removed from the patient's chart.

patients with a documented allergy to amoxicillin, ampicillin, or penicillin who are deemed low-risk for true penicillin allergy based on history will be offered enrollment in the study. patients will be scheduled for an oral amoxicillin challenge in the primary care office at a later date. during this challenge, patients will be given 10% of a weight-based dose of amoxicillin and then observed for 30 minutes for signs and symptoms of an allergic reaction. if no reaction occurs, they will be given the remaining 90% of the weight-based dose and observed for an additional 30 minutes. emergency medications such as diphenhydramine and epinephrine will be immediately available if needed. if the patient completes oral amoxicillin challenge without a clinically significant reaction, penicillin (and/or amoxicillin/ampicillin) allergy will be removed from the patient's chart.

Eligibility criteria:
inclusion criteria: * patients less than 18 years old who attend either of two hospital-affiliated general pediatric clinic sites who have an allergy to penicillin (or its derivatives) documented in their electronic medical record. exclusion criteria: * patients who do not have an allergy to penicillin (or its derivatives) documented in their electronic medical record or patients with listed penicillin allergy whose parent/guardian declines to participate in the study. patients will also be excluded if their penicillin allergy has been confirmed with either failed amoxicillin challenge or positive penicillin skin testing. medically fragile children who cannot tolerate a direct oral challenge will be excluded but may be offered referral to allergy/immunology. if, on review of the history of the allergy, features of likely ige mediated (onset in 1st hour of course or anaphylaxis requiring hospital care) or dangerous non-ige mediated penicillin allergy (stevens johnson with penicillin, blistering rashes, penicillin related cytopenia) are obtained, these patients are also excluded from challenge but may be referred to allergy for further education and appropriate testing.
nlcr in prediction of the grade of lung tumor.

Conditions: Lung Neoplasm

Summary: the aim of the study is to assess whether the value of neutrophil-lymphocyte count ratio from the routine preoperative blood test may predict lung tumors' grading.

lung cancer remains as one of the leading causes of death among oncology patients. close connection between inflammation and pathogenesis of some neoplasms was determined in a number of studies. some studies show promise that ratio of neutrophil to lymphocyte count (nlcr) may be recognized as a prognostic marker for several carcinomas: renal, lung and colorectal. the aim of the study is to assess whether the value of neutrophil-lymphocyte count ratio from the routine preoperative blood test may predict lung tumors' grading. during routine preoperative blood tests complete blood count is done and nlcr, wbc, neutrophil and lymphocyte count is noted. after the thoracic surgery intervention and histopathological examination grading of lung tumor is noted.

Eligibility criteria:
inclusion criteria: * consecutive thoracic surgery patients with lung cancer grading confirmed by histopathology postoperatively * preoperative routine complete blood count analysis exclusion criteria: * infectious disease * pregnancy * autoimmunologic disease * other known conditions or treatments that may influence the blood count (seropositivity for hiv, chemotherapy, and corticotherapy)

Keywords: nlcr, the neutrophil-lymphocyte count ratio, lung neoplasm
feasibility study of telemedicine for dialysis patients awaiting transplantation

Conditions: End Stage Renal Disease; Kidney Disease, Chronic

Summary: the purpose of this study is to determine whether a telemedicine follow-up visit at the nyu langone transplant institute is a feasible and acceptable alternative to a traditional in-center follow-up visit.

a six-month prospective randomized-controlled clinical pilot study to evaluate a new intervention for the transplant program: telemedicine (tm) visits. researchers will target patients on the transplant waiting list who are currently undergoing dialysis. currently, there are 234 patients on the transplant waiting list who receiving care at dialysis centers in the new york city area. researchers will select the 10 dialysis centers having the highest number of patients on the transplant list in order to yield a target sample of 45. eligible participants will be randomized to 1 of 2 groups: (1) usual care (uc) which is the routine 6-month follow up appointment at the nyulmc transplant center or (2) tm visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit. patients will be followed for 4 months post randomization to determine the number of days that elapse between randomization and routine transplant evaluation. as new clinic appointments are currently experiencing 80-day wait, a 4-month follow-up should be more than adequate to evaluate this primary outcome. the intervention will be evaluated primarily in terms of efficiency, and secondarily in terms of patient/physician experiences, changes in waiting list status, and referral for living donation.

Eligibility criteria:
inclusion criteria: * receiving thrice-weekly hemodialysis treatment for 6 months * on nyulmc kidney transplant wait list exclusion criteria: * unable or unwilling to provide informed consent * unable to read or otherwise use an ipad (e.g. blind)

Keywords: telemedicine
thin bronchoscope and virtual bronchoscopic navigation system for tuberculosis

Conditions: Tuberculosis

Summary: this study investigates the utility of thin bronchoscope and virtual bronchoscopic navigation system (targeted bronchial washing) for detection of m. tuberculosis and resistant-conferring mutations in patients with pulmonary tuberculosis. time to appropriate treatment and stain/culture conversion are also evaluated.

comparisons of detection rate of m. tuberculosis and resistant-conferring mutations between patients who perform ct-guided conventional bronchoscope and patients who perform vbn-guided thin bronchoscope.

Eligibility criteria:
inclusion criteria: * age of 18 or more * persons who are suspected with pulmonary tuberculosis on radiologic examination * persons who cannot spit sputum or persons with negative results on sputum afb smear and tb-pcr or xpert mtb/rif assay exclusion criteria: * persons who do not agree with bronchoscopy (persons who want empirical treatment for tb) * persons with contraindications for bronchoscopy * bleeding tendency * uncontrolled respiratory disease (hypoxemia) * uncontrolled cardiovascular disease
using bedside ultrasound to screen for sarcopenia in older adults

Conditions: Sarcopenia

Summary: the loss of both muscle mass and quality with increasing age is called 'sarcopenia' and is a risk factor for falls, fractures and increased mortality. sarcopenia is diagnosed with dual-energy x-ray absorptiometry (dxa) scanning (according to current criteria), but in canada dxa scans are not approved to screen for this condition. one potential solution is point of care ultrasound (pocus), since recent advances have made bedside ultrasound technology readily available as a rapid bedside screening tool.

some recent work has examined the possibility of using ultrasound as a measure of both muscle quantity and muscle quantity. work done by strasser et al, has shown that ultrasonic measures of muscle thickness in the quadriceps muscle has a highly significant correlation with maximal voluntary contration. other work done by miron-mombiela et al has shown that measures of muscle thickness and echointensity (a measure of muscle quality) also show high correlations with grip strength. these findings (supported by our pilot data, see pilot data) and new technological advances in bedside ultrasonic devices suggest that these measures might be a valuable contribution to the process of screening for sarcopenia in older adults. in this proposal, investigators hypothesize that bedside ultrasound, which is increasingly becoming a mainstream component of the standard physical exam, will be a much more specific and accurate alternative to our current best screening methods.

Eligibility criteria:
inclusion criteria: * each subject must be 65 years of age or greater exclusion criteria: * hemodialysis patients will be excluded, due to excessive fluid shifts with dialysis * patients using chronic oral corticosteroids will be excluded, due to potential muscle atrophy * hemiparesis due to a stroke or paresis of the lower limbs will be excluded * subjects with pitting edema on physical exam (due to liver, renal or heart failure) or patients that are severely dehydrated will be excluded * patients with myositis, systemic connective tissue disorders, systemic atrophies affecting the central nervous system (cns) and cns demyelinating diseases will be excluded
time restricted feeding on weight loss and cardio-protection (treaty trial)

Conditions: Obesity; Time Restricted Feeding; Weight Loss; Calorie Restriction

Summary: time restricted feeding (trf) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. this is a randomized controlled trial to evaluate the effect of time restricted feeding (trf) on weight loss and cardiometabolic risk factors in obese adults over 12 months compared to continuous energy restriction (cer).


Eligibility criteria:
inclusion criteria: 1. male of female aged between 18 and 75 years old; 2. body mass index (bmi)of 28.0 to 45.0 kg/m2; exclusion criteria: 1. history of hiv, hepatitis b or c (self-report) or active pulmonary tuberculosis; 2. diagnosis of type 1 and type 2 diabetes; 3. history of malignant tumors; 4. serious liver dysfunction or chronic kidney disease (ast or alt \> 3 times the upper limit of normal, or egfr\<30 ml/min/1.73 m2); 5. history of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months; 6. history of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months; 7. history of cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity; 8. being a smoker or having been a smoker in the 3 months prior to their screening visit; 9. taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician; 10. currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) ; 11. women who are pregnant or plan to become pregnant; 12. patients who cannot be followed for 24 months (due to a health situation or migration); 13. patients who are unwilling or unable to give informed consent.
study of retinal sensitivity by microperimetry during epiretinal membrane surgery

Conditions: Epiretinal Membrane Surgery

Summary: the aim of this research is to assess current care by studying macular function using microperimetry and by then comparing visual acuity results with oct (optical coherence tomography) data. the examinations performed are those usually done in the follow-up of epiretinal membrane surgery, apart from microperimetry which is an examination of the central visual field. patients who undergo erm surgery usually have a follow-up examination at 1 month, 3 months and 6 months after the surgery. the consultation includes an assessment of visual acuity, a fundus examination an sd-oct of the retina. the present protocol will require no additional visits. the microperimetry will be done in addition to the usual follow-up examinations after erm surgery.


Eligibility criteria:
inclusion criteria: * persons who have provided consent, * patients about to undergo idiopathic epiretinal membrane surgery, * patients undergoing first-line macular surgery exclusion criteria: * persons not covered by national health insurance * preexisting disease of macula/epiretinal membrane (armd, chorioretinal scarring) * preoperative amblyopic eye * insufficiently transparent media making it impossible to do the examinations
a trial for the treatment of cardiac al-amyloidosis with the green tea compound epigallocatechin-3-gallate (tame-al)

Conditions: Light Chain (AL) Amyloidosis; Cardiac Involvement

Summary: efficacy and safety of epigallocatechin-3-gallate (egcg) in patients with cardiac amyloid light-chain (al) amyloidosis. evaluation of clinical efficacy of egcg intake using a pretest posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac mri.


Eligibility criteria:
inclusion criteria: * biopsy proven systemic al amyloidosis. * cardiac involvement with septum thickness more than 12 mm (without other causes as published by gertz et al., hypertension or other potential causes of left ventricular hypertrophy) * previously treated with chemotherapy, induced at least a very good partial remission of the underlying monoclonal plasma cell or b cell disorder. * gpt and got less than 3-times uln. * life expectancy more than 12 month. * ability of subject to understand character and individual consequences of the clinical trail. * written informed consent. * for women with childbearing potential and men, adequate contraception. exclusion criteria: * age less than 18 years. * concomitant multiple myeloma stage 2 and 3 (salmon and durie) * concurrent chemotherapy necessary * time to last chemotherapy more than 6 months. * chronic liver disease, bilirubin over 1,5 mg/dl * not able to visit amyloidosis clinic in heidelberg every 3 months. * history of hypersensitivity to the investigational product or to any substance with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * participation in other clinical trials or observation period of competing trials, respectively. * pregnant or nursing women.

Keywords: amyloidosis
computer-based behavior change guide in increasing physical activity in patients with prostate cancer who have received androgen deprivation therapy

Conditions: Prostate Carcinoma

Summary: this randomized pilot clinical trial studies how well a computer-based behavior change guide works in increasing physical activity in patients with prostate cancer who have received androgen deprivation therapy. a computer-based behavior change guide website may increase physical activity level for prostate cancer survivors and help doctors understand what outcomes related to becoming physically active are most important to patients with prostate cancer.

primary objectives: i. engage with prostate cancer patients (pcps) who have received or are currently on androgen deprivation therapy (adt) to develop a computer-based behavior change guide (bcg) for pcps to provide fundamental information about benefits of exercise for their individual capabilities and goals and provide a personalized physical activity plan. (development phase) ii. engage with pcps to understand what outcomes are most important to them related to becoming active (e.g., helped me manage side-effects of treatment, reduced fatigue) and develop measures to evaluate these patient-centered outcomes. (development phase) iii. evaluate the bcg in a study comparing the personalized computer-based bcg with physical activity recommendations provided via a passive website (american cancer society guidelines on nutrition and physical activity for cancer survivors) among pcps who have received adt. (evaluation phase) outline: development phase: patients view mock-ups of the bcg web design on a computer, ipad, or printed color paper and provide feedback with a one-on-one interview or separately using the think/talk aloud method followed by a one-on-one interview. after completion of these design rounds, patients use the bcg website and provide individual feedback. evaluation phase: patients are randomized to 1 of 2 groups. group i: patients use the bcg website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. patients then receive a report with a personalized physical activity plan. group ii: patients use a passive website (american cancer society guidelines on nutrition and physical activity for cancer survivors). after completion of study, patients are followed up at 2 months.

Eligibility criteria:
inclusion criteria: * prostate cancer (pca) diagnosis * able to read english on a computer screen * signed an institutional review board (irb)-approved informed consent * evaluation phase * underactive (defined as physically active for less than 30 minutes per day fewer than 2 days per week) * access to a computer at home or public location exclusion criteria: * non-english speaking subjects are excluded from this study; the website being developed will only be available in english
a safety, pharmacokinetic and pharmacodynamic study of pur0200 in copd patients

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to assess the safety and tolerability of pur0200. in addition, the study will look at the blood levels of different doses of pur0200 and their affect on lung function in copd patients.

this is a multi-center, 2-part, pharmacokinetic (pk), pharmacodynamic (pd) effect, safety and tolerability study of single doses of pur0200.

Eligibility criteria:
key inclusion criteria: * a clinical diagnosis of moderate to severe copd according to the following criteria: * current or ex-smokers with at least 10 pack-year smoking history * post-bronchodilator fev1 \>/= 35% and \</= 80% of predicted normal value * post-bronchodilator fev1/fvc (forced vital capacity) ratio \<0.70 * post-bronchodilator improvement in fev1 \>/= 100 ml key exclusion criteria: * current evidence or recent history of clinically significant or unstable disease (other than copd) * current diagnosis of asthma * presence of history of clinically significant allergy requiring treatment * copd exacerbation within 6 weeks * use of daily oxygen therapy \> 10 hours * thoracotomy with pulmonary resection * use of systemic steroids within 3 months * lower respiratory tract infection within 30 days * upper respiratory tract infection within 30 days requiring treatment with antibiotics * history of tuberculosis, bronchiectasis, or other non-specific pulmonary disease * prolonged corrected qt (qtc) interval \>450 msec males and \>470 msec females, or history of long qt syndrome

Keywords: copd chronic obstructive pulmonary disease